TR200101592T2 - Faktör VIII ifade sistemi. - Google Patents

Faktör VIII ifade sistemi.

Info

Publication number
TR200101592T2
TR200101592T2 TR2001/01592T TR200101592T TR200101592T2 TR 200101592 T2 TR200101592 T2 TR 200101592T2 TR 2001/01592 T TR2001/01592 T TR 2001/01592T TR 200101592 T TR200101592 T TR 200101592T TR 200101592 T2 TR200101592 T2 TR 200101592T2
Authority
TR
Turkey
Prior art keywords
factor viii
protein
procoagulant activity
cells
free
Prior art date
Application number
TR2001/01592T
Other languages
English (en)
Inventor
Cho Myung-Sam
Chan Sham-Yuen
Kelsey William
Yee Helena
Original Assignee
Bayer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corporation filed Critical Bayer Corporation
Publication of TR200101592T2 publication Critical patent/TR200101592T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Bu bulus faktör VIII prokoagülan aktivitesine sahip proteinler için proteinsiz bir üretim islemini tarif etmektedir. Genel olarak, islem yüksek B-alani silinmis Faktör VIII verimi olan dengeli insan hücre çizgisi klonlarinin türetilmesi, ve (2) hücrelerin plazma türevli proteinler içermeyen bir ortamda yetismek üzere uyarlanmasini içerir. Daha özel olarak, islem, insan hücrelerinin, sekildeki gibi, bir seçilebilir isaret ve faktör VIII prokoagülan aktivitesine sahip proteini kodlayan bir dizi içeren bir vektörle transfekte edilmesini, hücrelerin bir seçim maddesi ile seçilmesini ve faktör VIII prokoagülan aktivitesine sahip proteini yüksek seviyelerde ifade eden klonlarin izole edilmesini içerir.
TR2001/01592T 1998-12-10 1999-12-08 Faktör VIII ifade sistemi. TR200101592T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII

Publications (1)

Publication Number Publication Date
TR200101592T2 true TR200101592T2 (tr) 2001-11-21

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01592T TR200101592T2 (tr) 1998-12-10 1999-12-08 Faktör VIII ifade sistemi.

Country Status (26)

Country Link
US (10) US6358703B1 (tr)
EP (1) EP1137797B1 (tr)
JP (1) JP4240818B2 (tr)
KR (1) KR100616028B1 (tr)
AT (1) ATE412765T1 (tr)
AU (1) AU761801B2 (tr)
BG (1) BG65431B1 (tr)
BR (1) BRPI9916069B8 (tr)
CA (1) CA2354845C (tr)
CZ (1) CZ302330B6 (tr)
DE (1) DE69939839D1 (tr)
DK (1) DK1137797T3 (tr)
ES (1) ES2315026T3 (tr)
HU (1) HU228489B1 (tr)
IL (2) IL143353A0 (tr)
NO (1) NO329544B1 (tr)
NZ (1) NZ512234A (tr)
PL (1) PL200676B1 (tr)
PT (1) PT1137797E (tr)
RO (1) RO121604B1 (tr)
RU (1) RU2249041C2 (tr)
SI (1) SI20644B (tr)
SK (1) SK286945B6 (tr)
TR (1) TR200101592T2 (tr)
UA (1) UA77383C2 (tr)
WO (1) WO2000034505A1 (tr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
IL151857A0 (en) * 2000-03-22 2003-04-10 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
JP4361786B2 (ja) * 2001-06-14 2009-11-11 ザ スクリプス リサーチ インスティチュート 操作されたジスルフィド結合を有する安定化蛋白質
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
CA2526120A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
CA2585547A1 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
LT3130601T (lt) * 2004-11-12 2020-09-10 Bayer Healthcare Llc Į vietą nukreipta fviii modifikacija
TWI423986B (zh) 2005-12-20 2014-01-21 必治妥美雅史谷比公司 組合物及製造組合物之方法
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
JP5727790B2 (ja) 2007-12-27 2015-06-03 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 細胞培養プロセス
KR101005967B1 (ko) 2008-04-12 2011-01-05 (주)셀트리온 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
KR20110033242A (ko) * 2008-06-25 2011-03-30 바이엘 헬스케어 엘엘씨 면역원성이 감소된, 인자 ⅷ 뮤테인
KR101921698B1 (ko) 2008-08-21 2018-11-26 옥타파마 아게 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ
PT2337580E (pt) * 2008-09-03 2012-05-28 Octapharma Ag Composições estabilizadas para o factor viii produzido de forma recombinante
DK2393828T3 (en) 2009-02-03 2017-01-23 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US20120142593A1 (en) * 2009-03-24 2012-06-07 Bayer Healthcare Llc Factor VIII Variants and Methods of Use
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
EP2707387B1 (en) * 2011-05-13 2019-12-25 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
KR102212098B1 (ko) 2012-01-12 2021-02-03 바이오버라티브 테라퓨틱스 인크. 키메라 인자 viii 폴리펩티드들과 이의 용도
US10370430B2 (en) 2012-02-15 2019-08-06 Bioverativ Therapeutics Inc. Recombinant factor VIII proteins
SG11201404885RA (en) * 2012-02-15 2014-09-26 Amunix Operating Inc Factor viii compositions and methods of making and using same
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
BR112016015512B1 (pt) 2014-01-10 2023-12-19 Bioverativ Therapeutics Inc Proteína quimérica, composição farmacêutica e seus usos
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
EA201892347A1 (ru) 2016-04-15 2019-04-30 Баксалта Инкорпорейтед Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов
WO2018017923A1 (en) 2016-07-22 2018-01-25 Nektar Therapeutics Conjugates of a factor viii moiety having an oxime-containing linkage
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. OLIGOSACCHARIDE COMPOSITIONS AND THEIR USE DURING THE TRANSIENT PHASES OF INTESTINAL MICROBIOMA OF A MAMMALIAN
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
EP3870206A4 (en) * 2018-10-23 2023-04-26 The Children's Hospital Of Philadelphia COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (ko) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 지폐류 판별장치
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
ATE63335T1 (de) * 1986-07-11 1991-05-15 Miles Inc Herstellung von rekombinantem protein.
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
US5171844A (en) * 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
DE69433925T2 (de) * 1993-06-10 2005-07-28 Bayer Corp. Vektoren und Zelllinien von Säugetieren mit erhöhter Produktivität
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (de) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere
MX9504215A (es) 1995-10-05 1997-04-30 Inst Politecnico Nacional Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus

Also Published As

Publication number Publication date
KR20020013481A (ko) 2002-02-20
HU228489B1 (en) 2013-03-28
JP2002531137A (ja) 2002-09-24
PL200676B1 (pl) 2009-01-30
NO329544B1 (no) 2010-11-08
US9650431B2 (en) 2017-05-16
KR100616028B1 (ko) 2006-08-28
EP1137797A1 (en) 2001-10-04
US20020115152A1 (en) 2002-08-22
EP1137797A4 (en) 2005-06-22
US20130143818A1 (en) 2013-06-06
NO20012718D0 (no) 2001-06-01
UA77383C2 (uk) 2006-12-15
RO121604B1 (ro) 2007-12-28
SK286945B6 (sk) 2009-08-06
HUP0200558A3 (en) 2004-11-29
US20090036358A1 (en) 2009-02-05
PT1137797E (pt) 2008-12-26
RU2249041C2 (ru) 2005-03-27
SI20644A (sl) 2002-02-28
US6358703B1 (en) 2002-03-19
WO2000034505A1 (en) 2000-06-15
DE69939839D1 (de) 2008-12-11
ATE412765T1 (de) 2008-11-15
US9249209B2 (en) 2016-02-02
SK7922001A3 (en) 2002-01-07
DK1137797T3 (da) 2009-02-23
EP1137797B1 (en) 2008-10-29
JP4240818B2 (ja) 2009-03-18
US20130267468A1 (en) 2013-10-10
AU2170100A (en) 2000-06-26
BG65431B1 (bg) 2008-07-31
BR9916069A (pt) 2001-09-04
US8945869B2 (en) 2015-02-03
SI20644B (sl) 2009-04-30
US8207117B2 (en) 2012-06-26
US20110144025A1 (en) 2011-06-16
BG105567A (en) 2002-03-29
BRPI9916069B1 (pt) 2016-08-02
NO20012718L (no) 2001-06-01
HUP0200558A2 (en) 2002-06-28
CZ20012024A3 (cs) 2001-10-17
CZ302330B6 (cs) 2011-03-16
CA2354845A1 (en) 2000-06-15
CA2354845C (en) 2008-08-12
US20160115219A1 (en) 2016-04-28
US20170267745A1 (en) 2017-09-21
BRPI9916069B8 (pt) 2021-05-25
IL143353A (en) 2010-12-30
US20030077752A1 (en) 2003-04-24
PL349284A1 (en) 2002-07-15
AU761801B2 (en) 2003-06-12
NZ512234A (en) 2002-12-20
IL143353A0 (en) 2002-04-21
ES2315026T3 (es) 2009-03-16
US7459525B2 (en) 2008-12-02
US20020102730A1 (en) 2002-08-01

Similar Documents

Publication Publication Date Title
TR200101592T2 (tr) Faktör VIII ifade sistemi.
ATE389666T1 (de) Hohe expressionsrate von proteinen
HUP0001650A2 (hu) Javított expressziós vektorok
DE69635452D1 (de) Hohe expressionsrate des grün-fluoreszierenden proteins
AU1750297A (en) Humanized green fluorescent protein genes and methods
DE69634640D1 (de) Mutierte alpha-amylase enzyme mit erhöhter stabilität
ES2013324A6 (es) Un metodo mejorado para producir una proteina heterologa.
ES2177475T1 (es) Genes de corynebacterium glutamicum que codifican proteinas de una ruta metabolica.
ATE312186T1 (de) Vektoren und verfahren für rekombinante proteinexpression
GB8424832D0 (en) Cdna clones coding
DE60128149D1 (en) Putrescin-n-methyltransferasepromotor
PT1025245E (pt) Criacao rapida de linhas celulares estaveis de mamifero produzindo elevados iiveis de proteinas recombinantes
FI962268A0 (fi) Homologinen, rekombinanttinen vasta-aineilmentämisjärjestelmä rottien tai hiirien soluille
DK0811071T3 (da) Amplifikeringssekvenser hidrørende fra desmin-genet, vektorer indeholdende disse sekvenser og anvendelse heraf til fremstilling af proteiner
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
DK1007627T3 (da) Extracellulær serinprotease
ES8405842A1 (es) Procedimiento de producir razas estables de celulas de mamiferos
ATE266094T1 (de) Produktion des proteins ingap mit hoher expressionsrate
HUP9902585A2 (hu) Replikálódó molekulák in vivo előállítása
WO1997012974A3 (en) Kidney atp-dependent potassium channels
AU1847597A (en) Transduced human hematopoietic stem cells
ATE318920T1 (de) Promotoren zur genexpression in karyopsen von pflanzen